BioLamina, a Stockholm-based biotechnology firm, has successfully secured a €20 million loan from the European Investment Bank (EIB). This funding will significantly bolster the company’s efforts to expand its production of laminin-based cell culture matrices, which are crucial for developers involved in stem cell therapies worldwide.
A Key Player in Cell Therapy
BioLamina occupies a pivotal position within the cell therapy ecosystem. Instead of directly developing therapies, the company specializes in producing extracellular matrix proteins essential for the reliable growth, expansion, and differentiation of stem cells outside the human body. This capability is vital for advancing various therapeutic applications, as it supports researchers and companies in creating effective cell-based treatments.
The Science Behind Laminins
The company’s flagship product, Biolaminin®, comprises full-length human recombinant laminin proteins. These proteins mirror the natural environment of cells, which is critical for their proper functioning. Laminins serve as fundamental structural components of the basement membrane, a protein layer that underlies epithelial and endothelial cells. They play a significant role in regulating cellular behaviors such as adhesion, survival, differentiation, and organization.
In contrast to most commercial alternatives, which often utilize truncated or non-human laminins, BioLamina emphasizes the importance of full-length human laminins. They argue that these proteins create more biologically accurate conditions, resulting in cell products that are more consistent, reproducible, and compliant with clinical regulations.
Broad Therapeutic Applications
The potential therapeutic uses of cells cultured on laminin matrices are extensive. These cell therapies could pave the way for innovative treatments for conditions such as type 1 diabetes through the generation of insulin-producing beta cells, as well as other serious illnesses like Parkinson’s disease, heart failure, acute liver failure, and various cancers. Many of these conditions currently lack effective treatments or cures.
Strategic Collaborations
BioLamina has established significant collaborations with notable industry players. For instance, the company has partnered with Novo Nordisk to develop stem cell therapies aimed at diabetes management. Additionally, it has joined forces with Cell X Technologies to enhance iPSC-based therapeutic manufacturing workflows. These partnerships not only bolster BioLamina’s research capabilities but also underscore its commitment to advancing the field of cell therapy.
Company Background and Investors
Founded in 2008, BioLamina emerged from research conducted in Dr. Karl Tryggvason’s laboratory at the Karolinska Institutet and Duke-NUS Medical School. The company is headquartered in Sundbyberg, Greater Stockholm, and employs approximately 100 to 117 staff members, depending on various reports.
The principal shareholders of BioLamina include Swedish investment company Bure Equity AB, Lauxera Capital Partners, the Tryggvason family, and Northislet. In July 2024, the company raised €19 million in equity financing, primarily led by Lauxera Capital Partners, further demonstrating its strong financial backing.
EIB Loan and Future Prospects
The €20 million loan from the EIB marks BioLamina’s first publicly disclosed debt financing and aligns with the EIB’s broader BioTechEU initiative, which aims to mobilize €10 billion in biotech investments from 2026 to 2027.
CEO Klaus Langhoff-Roos has articulated BioLamina’s mission as demonstrating that “full-length equals full-function.” This philosophy extends to the company’s drug safety testing products, which provide animal-free alternatives to traditional animal-derived extracellular matrices used in toxicology screenings. The EIB loan will support both BioLamina’s core business in cell therapy and its innovative drug safety testing efforts.
Conclusion
BioLamina’s recent funding acquisition is a promising step toward advancing cell therapy technologies and enhancing drug safety testing methods. As the company continues to expand its production capabilities and strengthen strategic partnerships, it solidifies its role as a cornerstone in the ever-evolving landscape of biotechnology. With a commitment to innovation and ethical practices, BioLamina is poised to contribute significantly to the future of medical treatments.
- BioLamina secures €20M loan from EIB to scale production.
- Focus on full-length human laminins for cell therapy applications.
- Broad therapeutic potential for conditions like diabetes and cancer.
- Strategic partnerships enhance research and manufacturing capabilities.
- Aligns with EIB’s BioTechEU initiative for biotech investments.
Read more → thenextweb.com